About Ancora heart, inc.
Ancora Heart, Inc. - Revolutionizing the Treatment of Heart Failure
Heart failure is a serious medical condition that affects millions of people worldwide. It occurs when the heart is unable to pump enough blood to meet the body's needs, leading to symptoms such as shortness of breath, fatigue, and swelling in the legs and ankles. Despite advances in medical technology, heart failure remains a major health concern with limited treatment options.
Enter Ancora Heart, Inc., a medical device company that has developed AccuCinch®, the first percutaneous ventricular restoration system designed to treat heart failure. The company's innovative approach has garnered attention from healthcare professionals and patients alike.
Founded in 2015 by Dr. Jeffery Ardell and Dr. Igor Efimov, Ancora Heart is headquartered in Santa Clara, California. The company's mission is to improve patient outcomes by developing breakthrough technologies for treating cardiovascular diseases.
AccuCinch® - A Game-Changing Solution for Heart Failure
AccuCinch® is a minimally invasive procedure that involves placing a small device around the heart's left ventricle (LV). The device works by cinching or tightening the LV muscle wall which helps restore its normal shape and function.
The AccuCinch® procedure takes about an hour to complete under local anesthesia with conscious sedation or general anesthesia depending on patient preference or physician recommendation. Patients typically go home within 24 hours after their procedure.
Clinical trials have shown promising results for AccuCinch® as an effective treatment option for patients with symptomatic heart failure who are not responding well to medication therapy alone or are not candidates for other surgical interventions like cardiac resynchronization therapy (CRT) or left ventricular assist devices (LVADs).
In one study published in JACC: Cardiovascular Interventions Journal in 2020 involving 49 patients across six centers globally who underwent AccuCinch®, there was significant improvement observed at six months post-procedure compared with baseline measurements including:
- A reduction of LV end-systolic volume index (LVESVi) by an average of 19%
- An increase of ejection fraction (EF) by an average of 8%
- Improvement in New York Heart Association (NYHA) functional class
- Reductions in N-terminal pro-B-type natriuretic peptide levels
These results demonstrate that AccuCinch® can help improve cardiac function while reducing symptoms associated with heart failure.
Ancora Heart - Committed to Advancing Cardiac Care
Ancora Heart has received several grants from organizations such as National Institutes of Health (NIH), American College of Cardiology Foundation Innovation Award Program among others which have helped fund research into new treatments for cardiovascular diseases including atrial fibrillation ablation techniques using high-frequency ultrasound energy delivery systems called HIFU catheters.
The company also collaborates closely with leading cardiologists and researchers worldwide through clinical trials aimed at advancing cardiac care further while improving patient outcomes significantly.
Conclusion
Heart failure remains one of the most challenging conditions facing healthcare providers today due to its complexity and limited treatment options available currently. However, Ancora Heart's innovative approach using AccuCinch® offers hope for those suffering from this debilitating disease who may not be candidates for other surgical interventions like CRTs or LVADs but still need relief from their symptoms associated with it.
With its commitment towards advancing cardiac care through research collaborations globally alongside grants received over time; Ancora Hearts' future looks bright indeed!